Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). (Q48547616)

12 February 2018

title

Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). (English)

1 reference

12 February 2018

0 references

1 reference

M J Postma

1 reference

12 February 2018

J M Bos

1 reference

12 February 2018

Ph Beutels

1 reference

12 February 2018

H Schilthuis

1 reference

12 February 2018

J A R van den Hoek

1 reference

12 February 2018

language of work or name

English

0 references

publication date

1 May 2004

1 reference

12 February 2018

published in

Vaccine

1 reference

12 February 2018

volume

1 reference

12 February 2018

issue

15-16

1 reference

12 February 2018

page(s)

1862-1867

1 reference

12 February 2018

Clinical manifestations and diagnosis of hepatitis A virus infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Cost effectiveness of alternative hepatitis A immunisation strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Immunogenicity of inactivated hepatitis A vaccine in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

The effectiveness and safety of hepatitis A vaccine: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Cost-effectiveness analysis of vaccination against hepatitis A in travellers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Cost effectiveness of hepatitis A virus immunisation in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Valuation of symptomatic hepatitis a in adults: estimates based on time trade-off and willingness-to-pay measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

Experience of hepatitis A vaccination during an outbreak in a nursery school of Tuscany, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.012

10.1016/J.VACCINE.2003.11.012

7 January 2021

Identifiers

DOI

1 reference

12 February 2018

1 reference

12 February 2018